Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 1669-1674, 2006. First published July 13, 2006; 10.1373/clinchem.2006.067249
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.067249v1
clinchem.2006.067249v2
52/9/1669    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barker, P. E.
Right arrow Articles by Omenn, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barker, P. E.
Right arrow Articles by Omenn, G. S.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2006;52:1669-1674.)
© 2006 American Association for Clinical Chemistry, Inc.

Overview

Standards for Plasma and Serum Proteomics in Early Cancer Detection: A Needs Assessment Report from the National Institute of Standards and Technology-National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18–19, 2005

Peter E. Barker1,a, Paul D. Wagner2, Stephen E. Stein3, David M. Bunk4, Sudhir Srivastava2 and Gilbert S. Omenn5

1 NIST-National Cancer Institute Cancer Biomarker Reference Laboratory,3 NIST Mass Spectrometry Data Center, and4 Analytical Chemistry Division, NIST, Gaithersburg, MD.
2 Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.
5 Center for Biomedical Proteomics and Center for Computational Medicine & Biology, University of Michigan, Ann Arbor, MI.

aAddress correspondence to this author at: NIST-NCI Cancer Biomarker Reference Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899-8311. E-mail peter.barker{at}nist.gov.


Abstract

NIST and the National Cancer Institute cosponsored a workshop on August 18–19, 2005, to examine needs for reference materials for early cancer detection. This meeting focused on standards, methods, assays, reagents, and technologies. Needs for plasma and serum proteomics, DNA methylation, and specimen reference collections were discussed, and recommendations from participants were solicited. This report summarizes the discussion and recommendations for proteomics reference materials.




The following articles in journals at HighWire Press have cited this article:


Home page
 BloodHome page
D. Cervi, T.-T. Yip, N. Bhattacharya, V. N. Podust, J. Peterson, A. Abou-Slaybi, G. N. Naumov, E. Bender, N. Almog, J. E. Italiano Jr, et al.
Platelet-associated PF-4 as a biomarker of early tumor growth
Blood, February 1, 2008; 111(3): 1201 - 1207.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.